Vineeta Shobha, Liza Rajasekhar, Sandra Manuel, V Nayana, Chengappa Kavadichanda, Deepika Kounassegarane, Ashish J Mathew, Ranjan Gupta, Manish Rathi, Parasar Ghosh, Saumya Ranjan Tripathy, Bidyut Das, Sumithra Selvam, Abhishek Kumar Singh, Ankita Singh, Avinash Jain, Amita Aggarwal
Antiphospholipid antibodies (APLA) are present in one-third of systemic lupus erythematosus (SLE) patients, and they are associated with both criteria and non-criteria manifestations. We studied the prevalence, clinical associations, and impact on mortality of APLA in SLE patients from India. Among the Indian SLE inception cohort (INSPIRE), patients who had data on all five routinely performed APLAs [lupus anticoagulant (LA), IgG and IgM anticardiolipin antibody (aCL) and anti-β2-glycoprotein I(β2GPI)] at enrolment were selected...
December 12, 2023: Rheumatology International